Bharat Biotech International Ltd announced the initiation of clinical trials in India for a new TB vaccine, Mtbvac.
Dr Arora says that the CoWIN portal would not accept the fourth dose.
Bharat Biotech’s iNCOVACC is an adenovirus vectored nasal vaccine.
Bharat Biotech developed the needle-free intranasal vaccine, BBV154, against COVID-19.
Bharat Biotech wants to conduct clinical trials on 5,000 individuals to test its intranasal COVID-19 vaccine.